AB1262 MORTALITY IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS: STUDY FROM A SINGLE UNIVERSITY HOSPITAL
Authors: F. Benavides-Villanueva, V. Calvo-Río, D. Prieto-Peña, A. Herrero-Morant, S. Al Fazazi, A. Martín-Gutiérrez, A. Sánchez López, C. Poo-Fernandez, L. Gabrie, R. Blanco
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) includes Granulomatosis with polyangiitis (GPA), Microscopic polyarteritis (MPA) and Eosinophilic granulomatosis with polyangiitis (EGPA). Due to clinical, prognostic, and therapeutic similarities between GPA and MPA, these diseases are usually included in the same group particularly in clinical Trials. EGPA have different clinical and therapeutic features. The clinical spectrum of GPA and MPA may be quite heterogeneous, from a local limited disease to a life-threatening entity [1]. Some studies reported global mortality rates ranging between 10% to almost 40%. [2,3]. This wide range may be due to series including small or heterogeneous series from different hospitals and different inclusion criteria. Moreover, therapy has improved in recent years. <h3>Objectives:</h3> To assess the mortality and the main causes of death in GPA and MPA in a single hospital. <h3>Methods:</h3> Observational study of patients with GPA and MPA from January 1; 2000 to December 31, 2023, in a single University Hospital in Northern Spain. AAV were classified accordingly to EULAR/ACR 2022 criteria. Person-year (PY) at risk was calculated for each patient as time from the date of diagnosis through the date of death. Mortality rates were expressed as cases by 10<sup>6</sup> habitants per year (95% IC) and the Case Fatality rate expressed as percentage (95% IC), the accumulative incidence of mortality was expressed in cases by 10<sup>3</sup> PY. The population data were obtained from the Regional Health Service's annual reports. We consider 2 groups of GPA and MPA: a) study group (dead patients) and b) Control group (remaining patients). <h3>Results:</h3> We studied 108 patients, mean age 63.2±14.6 years with 709 person-year (PY) (57 GPA; 52.8%)/51 MPA; 47.2%). Death was observed in 43 of 108 cases (39.8%), (study group). The General Mortality rate was 3.8/10<sup>6</sup> habitants per year (95% IC: 2.4-5.1). The case fatality rate was 41% (95% IC: 27.2-54.7). The accumulative incidence of death was 60.6/10<sup>3</sup>/PY (95% IC: 60-61.2). The main causes of death were infections (n=15; 34.9%), Major adverse cardiovascular events (MACE) (n=5; 11.6%), neoplasia, (n=4; 9.3%), renal complication (n=4; 9.3%) and pulmonary complications without infections (3n=3; 6.9%). Death was more frequent after 2 years (71.8%). (FIGURE 1A). Infections were the most frequent cause of death (15 patients, 34.9%) on early (&lt;6 months), late (&gt; years) and at any time (2000-2008, 2017-2023) (FIGURE 1B). As expected, neoplasms appear in long term follow-up (9.3%). The study group (dead patients) compared with control group show a non-significant more frequent MPA, constitutional symptoms, pulmonary and renal involvement at time of diagnosis (TABLE 1). <h3>Conclusion:</h3> Mortality rates, the Case Fatality rate and the accumulative incidence of mortality in GPA and PAM remains relatively high. Infections are the most frequent cause followed by MACE. <h3>REFERENCES:</h3> [1] Kitching AR, et al. https://doi.org/10.1038/s41572-020-0204-y. [2] Sims, C, et al.. https://doi.org/10.1097/RHU.0000000000001917. [3] Wallace, Z. S., et al. <i>Rheumatology (Oxford) 2020</i>. <b>Table 1.</b> Clinical features and analytical findings in 108 patients with GPA and MPA Comparison between the mortality group (study group) and the remaining patients (control group). <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> Fabricio Benavides-Villanueva: None declared, Vanesa Calvo-Río: None declared, Diana Prieto-Peña: None declared, A. Herrero-Morant: None declared, Salma Al Fazazi: None declared, Adrián Martín-Gutiérrez: None declared, Amparo Sánchez López: None declared, Claudia Poo-Fernandez: None declared, Ligia Gabrie: None declared, Ricardo Blanco Abbvie, Pfizer, Roche, Bristol-Myers-Squibb, Janssen, Lilly, Novartis, UCB and MSD., Abbvie, MSD and Roche.